Gelomics, a leading Australian biotech firm at the forefront of drug development innovation, is further strengthening its Scientific Advisory Board with the addition of Distinguished Professor Dietmar W. Hutmacher, PhD, MBA, and Professor Travis J. Klein, PhD. Following the recent appointment of Professor Dame Molly Stevens, FREng FRS, these new appointments reinforce our commitment to driving innovation and excellence in the global biotech landscape.

“We are thrilled to have Travis and Dietmar on our Scientific Advisory Board. Their ground-breaking work in biomaterial science, biofabrication and biomedical engineering will greatly accelerate our efforts to craft solutions for drug discovery and development, enabling life-saving treatments to reach patients in need quicker and safer than before.“

– Dr Christoph Meinert, CEO of Gelomics.

About Distinguished Professor Dietmar W. Hutmacher, PhD, MBA

Professor Hutmacher is a co-founder of Gelomics, and current Director of the Max Planck Queensland Centre for the Materials Science of Extracellular Matrices. He is globally recognised as a leader in tissue engineering and regenerative medicine. With an illustrious career that blends over decades of industrial and academic excellence, Professor Hutmacher has pioneered numerous biomedical innovations. Additionally, he has authored over 500 journal articles, edited 14 books, and holds an impressive h-index of 133 with over 75,000 citations. His role at Gelomics will leverage his extensive experience in translating scientific research into impactful commercial and clinical applications. This aims to advance our biomaterials technology to new heights.

About Professor Travis J. Klein, PhD

Professor Klein, also a co-founder of Gelomics, is a distinguished figure in the field of biomedical engineering at the Queensland University of Technology (QUT). As the leader of the Cartilage Regeneration Laboratory, he has been at the forefront of developing regenerative therapies for cartilage defects. His extensive work, which includes senior leadership roles within QUT and has garnered over 10,000 citations, will be invaluable as Gelomics continues to pioneer innovative, non-animal methodologies for drug development.

About Gelomics

Gelomics is an Australian biotech startup at the forefront of revolutionising drug development. Founded with a commitment to innovation and ethical research, Gelomics specialises in pioneering non-animal methodologies to accelerate the discovery of new drugs. Leveraging cutting-edge technology and a multidisciplinary approach, the company aims to provide more predictive and effective alternatives to traditional animal testing. Gelomics is dedicated to advancing human health by enabling scientists to grow human tissues in vitro, offering a groundbreaking platform for drug efficacy and safety assessment. With a focus on ethical practices and sustainability, Gelomics is setting a new standard in biotechnology. They are aiming to reshape the future of drug development globally.

Learn more about Gelomics’ innovative products and access our product catalogue: www.gelomics.com